Home > Back to Publisher > Report Information

Protein Therapeutics: Monoclonal Antibodies, Plasma Proteins, Vaccines, and Other Treatments, Global Market

Kalorama Information
December 1, 2008
250 Pages - SKU: KLI1646601

Abstract Table of Contents Search inside this report Related Reports

The substances utilized for what is commonly referred to as 'protein therapeutics' have one thing in common --- they are all composed primarily of á-amino acids; and these á-amino acids are linked together by a distinct chemical bond known as a “peptide” bond. Used in a variety of areas of medicine, they are among the most interesting pharmaceutical markets.

Above-Average Growth Rates

What makes protein therapeutics interesting? The market for protein-based therapeutics is one that is significant in its size and growing at a rate that is well above what one would call “average” for the therapeutics/pharmaceuticals industry. This makes them a continual topic of interest for researchers examining the pharmaceutical markets. Protein Therapeutics: (Monoclonal Antibodies, Plasma Proteins, Vaccines and Other Treatments) takes a detailed look at this market

The substances detailed in this report include:

Monoclonal Antibodies
Antithrombins
Cytokines
Growth Hormones
Hematopoietics
Insulin
Plasma Proteins
Vaccines

Miscellaneous

For each of these categories, market forecasts to 2012 are provided.

A Thriving Field with Abundant Competition

At the present time, there are at least 213 companies active in various aspects of protein-based therapeutics development. This is at, or greater than, the saturation level for the industry at this time. Presently, the industry is at equilibrium --- companies at the lower end leaving and entering at about the same rate and a small number of protein-based therapeutics companies being acquired by the more-established participants.

A Report That Answers Key Questions about the Market

Dr. Kenneth Krul, PhD has surveyed the marketplace and in this volume reviews the key findings and conclusions about the current state of protein therapeutics. The report features forecasts for the main groups of protein therapeutics. Among the questions answered in this report:

How large is the market; how fast is the market growing; and is such growth sustainable?
What does the pipeline of products that are expected to sustain this growth look like?
To what extent is the growth in this market dependent on production introduction versus price-point for these products?
Is the development pipeline filled with similar products or direct alternatives such that product competition will be strong enough to significantly affect price-point?
What is the industry structure like? What changes can be expected in the structure of the industry and how will these changes affect market size and growth?

TABLE OF CONTENTS

CHAPTER ONE: EXECUTIVE SUMMARY

Scope and Methodology
Market Analysis
Trends and Considerations

CHAPTER TWO: PEPTIDES, PROTEINS, ENZYMES AND ANTIBODIES

Peptides
Tachykinin Peptides
Vasoactive Intestinal Peptides
Pancreatic Polypeptide-Related Peptides
Opioid Peptides
Calcitonin Peptides
Other Peptides
Proteins
Enzymes
Coenzymes
Antibodies
Allotype

CHAPTER THREE: CLINICAL APPLICATIONS OF APPLICATIONS OF PROTEIN-BASED THERAPEUTICS

Advantages of Protein Therapeutics
Group I: Enzymes and Regulatory Proteins
Group II: Targeted Proteins
Group III:
Toward the Future

CHAPTER FOUR: MARKET ANALYSIS

Growth Rate
Forecast
Trending By Product Class
Vaccines Market Forecast
Antithrobins Market Forecast
Hematopoietics Market Forecast
Insulin Market Forecast
Growth Hormones Market Forecast
Plasma Proteins Market Forecast
Trending by Product Class
Pipeline

CHAPTER FIVE: COMPANY SNAPSHOTS

Agennix
Altus Pharmaceuticals
Amgen
Amylin Pharmaceuticals
Biogen IDEC
BioMarin Pharmaceutical, Inc.
Cell Genesys, Inc
Eli Lilly & Company
Genentech, Inc.
Genzyme Corporation
Human Genome Sciences
Medarex
Neose Technologies, Inc.
Novo Nordisk, Inc (USA)
Regeneron Pharmaceuticals, Inc.
Xoma, Ltd.

CHAPTER SIX: CONCLUSIONS AND STRATEGIC IMPLICATIONS

First Conclusion
Second Conclusion
Third Conclusion
Fourth Conclusion
Fifth Conclusion
Sixth Conclusion
Seventh Conclusion
Eighth Conclusion
Ninth Conclusion
Tenth Conclusion

APPENDIX A: GLOSSARY

TABLE OF EXHIBITS

CHAPTER ONE: EXECUTIVE SUMMARY

Table 1-1: Estimated Global Market for Protein-Based Therapeutics by Major Product Class: 2008 - 2018
Figure 1-1: Trending in the Global Market for Protein-Based Therapeutics: 2008 - 2018
Figure 1-2: Trending in the Protein-Based Therapeutics Global Market by Product Class: 2008 - 2018

CHAPTER TWO: PEPTIDES, PROTEINS, ENZYMES AND ANTIBODIES

Table 2-1: The Naturally Occurring Amino Acids
Table 2-2: Significant Peptides in Biological Functions
Table 2-3: Key Features of Immunoglobulin Isotypes
Table 2-4: Immunoglobulin Functional Properties

CHAPTER THREE: CLINICAL APPLICATIONS OF APPLICATIONS OF PROTEIN-BASED THERAPEUTICS

Table 3-1: Replacement Protein Therapeutics: Subgroup Ia
Table 3-2: Augmenting Protein Therapeutics: Subgroup Ib
Table 3-3: Protein Therapeutics with a Novel Function Activity: Subgroup Ic
Table 3-4: Protein Vaccines: Subgroup IIa
Table 3-5: Drug Delivery Protein Therapeutics: Subgroup IIb
Table 3-6: Protein Vaccines: Group III
Figure 3-1: Biotechnology-Based Therapeutics in Development by Product Category: 2008 (Growth Factors, Interferons, Interleukins, Monoclonal Antibodies (mAbs), Recombinant Hormones/Proteins, Vaccines, Others)
Figure 3-2: Biotechnology-Based Therapeutics in Development by Protein and Non-Protein Category: 2008
Figure 3-3: Biotechnology-Based Therapeutics in Development by Clinical Application (Disease State): 2008
Table 3-7: Protein-Based Therapeutics in Development: 2008
Figure 3-4: Distribution of Protein-Based Therapeutics in Development by Orphan and Non-Orphan Drug Categories: 2008
Figure 3-5: Distribution of Protein-Based Therapeutics in Development Type: 2008
Figure 3-6: Distribution of Protein-Based Vaccines in Development by Recombinant and Non-Recombinant Categories: 2008

CHAPTER FOUR: MARKET ANALYSIS

Table 4-1: Estimated Global Market for Protein-Based Therapeutics by Major Product Class: 2008 - 2018
Figure 4-1 : Trending in the Global Market for Protein-Based Therapeutics: 2008 - 2018
Figure 4-2: Trending in the Protein-Based Therapeutics Global Market by Product Class: 2008 - 2018
Figure 4-3: Trending in the Protein-Based Therapeutics Global Market by Product Class: 2008 - 2018
Figure 4-4: Biopharmaceutical Approvals by the United States FDA: 1988 - 2007
Table 4-2: Biopharmaceuticals Approved by the FDA: 2006 - 2008
Table 4-3: Global Markets for Cytokines, Vaccines and Hematopoietic Factors: 2008 - 2018
Table 4-4: Companies Engaged in Protein-Based Therapeutics Development

Protein Therapeutics: Monoclonal Antibodies, Plasma Proteins, Vaccines, and Other Treatments, Global Market

Share this report

Other tasks

Research Assistance

Related Markets

Vaccines Reports

Free Alert Me service